Kala Bio Inc is a biopharmaceutical company dedicated to developing innovative therapies for patients suffering from serious eye diseases
The company focuses on creating treatments that address unmet medical needs, particularly in areas where current options are limited or inadequate. Their research and development efforts are aimed at advancing novel drug delivery systems and formulations that enhance the effectiveness and safety of ophthalmic treatments. Through their commitment to scientific excellence and patient-centric solutions, Kala Bio strives to improve the quality of life for those affected by debilitating vision disorders.
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among the common traits that could lead to a short squeeze.
Kala Pharmaceuticals (NASDAQKALA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 08:00 AM. Here's what investors need to know about the announcement.
Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High-short interest and high-cost to borrow are among the common traits that could lead to a short squeeze.
Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High short interest and high cost to borrow are among the common traits that could lead to a short squeeze.
Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High short interest and high cost to borrow are among the common traits that could lead to a short squeeze.
Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High short interest and high cost to borrow are among the common traits that could lead to a short squeeze.
As of the close of business on Monday, 3/31, we captured the Top 10 Highest Short Interest % stocks within the Healthcare sector. The average short interest for stocks within the Healthcare sector stands at 3.06%. Therefore, the below stocks are showing a more pessimistic outlook than their peers within the respective sector.
Potential short squeeze plays gained steam in 2021 and continued through 2022 with new traders looking for the next huge move. High short interest and high cost to borrow are among the common traits that could lead to a short squeeze.
Potential short squeeze plays gained steam in 2021 and continued through 2022 with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze.
Potential short squeeze plays gained steam in 2021 and continued through 2022 with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze.
Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze.
Gainers Unicycive Therapeutics, Inc. (NASDAQUNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch Renazorb.
Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze.
